The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA.sub.B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA.sub.B receptor agonist.

The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABA.sub.B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA.sub.B receptor agonist.

The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.

Embodiments herein relate to an implantable device comprising a casing, a semi-permeable membrane plug at or near a first end of the casing, a piston, beads, and an opening for release of the beads from the implantable device within a body of a human or an animal; wherein the implantable device is configured to be implanted within the body of the human or the animal during delivery of the beads into the body of the human or the animal; wherein the beads comprise a core and a shell with the core being enclosed by the shell and the beads contain a drug; and wherein the implantable device is configured to produce a desired flow rate of elution of the drug from the implantable device when the implantable device is implanted within the body of the human or the animal.

The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA.sub.B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA.sub.B receptor agonist.

The present invention relates to a lipolysis composition comprising a biocompatible polymer that is surface-modified by an adipocyte-targeting or cell-penetrating peptide; and surface-modified gas-generating nanoparticles that contain fine-grained calcium carbonate crystals enclosed in the biocompatible polymer.

The present invention relates to solid composition of Tofacitinib and salt thereof, and process of manufacture thereof. The present invention relates to non-osmotic an extended release composition comprising Tofacitinib or salt thereof, mixture of polyethylene oxides along with one or more pharmaceutically acceptable excipient. The non-osmotic an extended release composition of Tofacitinib or salt thereof is used in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ulcerative Colitis.

The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.8, M.sup.1, M.sup.2, M.sup.3, M.sup.4, M.sup.5, M.sup.6 and M.sup.7 are each independently a member selected from the group consisting of H, C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; R.sup.4, R.sup.7 and R.sup.9 are each independently selected from the group consisting of C.sub.1-6 alkoxy and OH; R.sup.10 is a member selected from the group consisting of H, —OH, —OP(O)Me.sub.2,

##STR00002##

—O—(CH.sub.2).sub.n—OH and —O—(CH.sub.2).sub.m—O—(CH.sub.2).sub.o—CH.sub.3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L.sup.1 and L.sup.4 are independently selected from the group consisting of:

##STR00003##

wherein each M.sup.8 is independently a member selected from the group consisting of C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; each of L.sup.2 and L.sup.3 are independently selected from the group consisting of:

##STR00004##

and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.